Asthma
Conditions
Brief summary
The primary objective of this study is to demonstrate differences in ILC2 blood levels between asthma patients and control patients.
Detailed description
The secondary objectives of this study are: To show that ILC2 levels differ between asthma patients with a TH2 (helper T cell type 2) profile and asthma patients with a non-TH2 profile. A TH2 profile is defined as (for a given patient): * circulating eosinophils \> 500 mm\^3 at least once during the year AND * positive allergy skin or specific IgE (Immunoglobulin E) test AND * induced sputum eosinophil level \>3% of leukocytes AND * exhaled nitric oxide \> 25 ppb. To study the variation in ILC2 levels over time among asthma patients who obtained a good level of control compared to other patients. A good level of control is defined as: * no exacerbations during 6 months of followup (an exacerbation is defined as the un-planned need for care that modifies the patient's prescription for \>48h) * FEV1 (forced expiratory volume in 1 second) value current / FEV1 best value \> 0.8 * symptom levels correspond to an ACQ (Asthma Control Questionnaire) questionnaire score of \< 0.75 over the last 7 days
Interventions
BIOLOGICALILC2 levels in blood
The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
Sponsors
University Hospital, Montpellier
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
for Cases: * The subject has given his/her informed consent and signed the consent form * The subject is affiliated with or beneficiary of a medical insurance system * The subject has had asthma for over a year * The following are present in the patient's medical file: (i) a positive methacholine test (PC20 \< 16 mg/ml) OR (ii) reversibility \> 200 ml and 12% of the FEV1 after inhaling 400 µg or less of a short acting bronchodilator. * Treatment with \>= 1000 µg inhaled beclometasone equivalents
Exclusion criteria
for Cases: * The subject is pregnant * The subject is breastfeeding * The subject is participating in another interventional study * The subject has participated in another study in the 3 months preceding inclusion * The subject is in an exclusion period determined by a previous study * The subject is under judicial protection or is an adult under any kind of guardianship * The subject refuses to sign the consent * It is impossible to correctly inform the subject * The subject cannot fluently read French * Chronic respiratory disease present, known or suspected (other than asthma) * Treated with Montelukast Inclusion Criteria for Controls: * The subject has given his/her informed consent and signed the consent form * The subject is affiliated with or beneficiary of a medical insurance system
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| % ILC2 cells among total blood lymphocytes | Day 0 | Determined by flow cytometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| % ILC2 cells among total blood lymphocytes | 6 months | Determined by flow cytometry; Asthma patients only. |
Outcome results
None listed